{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003125","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2023-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.443598+00:00","generated_at":"2026-06-19T08:28:36.398151+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pediatrix Q4 GAAP EPS $0.29, adjusted $0.47; revenue $514M; 2023 EBITDA guidance $235-245M","bullets":["Net revenue $513.8M (+3.1% YoY); same-unit patient volume +4.1%; commercial payor mix improved 20 bps.","GAAP diluted EPS $0.29 vs $0.47; Adjusted EPS $0.47 vs $0.52; CARES Act benefit declined materially.","Adjusted EBITDA $66.5M vs $81.0M; full year 2022 Adjusted EBITDA $241.0M, GAAP EPS $0.74.","2023 preliminary Adjusted EBITDA guidance $235-245M, assuming no additional CARES Act funds.","Revenue cycle management vendor underperformance partly offset by vendor support; overhead costs reduced."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003125","json":"https://secwatch.observer/filing/0000950170-23-003125.json","markdown":"https://secwatch.observer/filing/0000950170-23-003125.md","text":"https://secwatch.observer/filing/0000950170-23-003125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000095017023003125/0000950170-23-003125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000095017023003125/md-20230217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:28:36.398151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09c64e70613f669c45eae440b7e54cb4fae52b02","claim":"Pediatrix Medical Group, Inc. reported financial results for the twelve months ended December 31, 2022.","evidence_excerpt":"On February 17, 2023, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months and twelve months ended December 31, 2022 (the “Fourth Quarter Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017023003125/0000950170-23-003125-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f884354247588c1d4c945ea224ef2539b604a16b","claim":"Pediatrix Medical Group, Inc. reported financial results for the three months ended December 31, 2022.","evidence_excerpt":"On February 17, 2023, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months and twelve months ended December 31, 2022 (the “Fourth Quarter Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017023003125/0000950170-23-003125-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}